255 related articles for article (PubMed ID: 18204237)
21. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
22. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
23. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
25. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
26. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
27. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
28. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
Baffa R; Reiss K; El-Gabry EA; Sedor J; Moy ML; Shupp-Byrne D; Strup SE; Hauck WW; Baserga R; Gomella LG
Tech Urol; 2000 Sep; 6(3):236-9. PubMed ID: 10963500
[TBL] [Abstract][Full Text] [Related]
29. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
30. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
Povelitsa EA; Nabyrov EA
Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
[TBL] [Abstract][Full Text] [Related]
31. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination.
Fracalanza S; Prayer-Galetti T; Pinto F; Navaglia F; Sacco E; Ciaccia M; Plebani M; Pagano F; Basso D
Urol Int; 2005; 75(1):57-61. PubMed ID: 16037709
[TBL] [Abstract][Full Text] [Related]
32. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Zhigang Z; Jieming L; Su L; Wenlu S
J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
[TBL] [Abstract][Full Text] [Related]
33. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
34. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
Rodríguez Duarte C; Aguillón J; Rodríguez H
Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
[TBL] [Abstract][Full Text] [Related]
35. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
36. PSA excess in the differential diagnosis of prostate carcinoma.
Díaz F; Morell M; Rojo G
Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
[TBL] [Abstract][Full Text] [Related]
37. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
38. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
39. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
